

PRESS RELEASE

Indoco's Q2FY20 revenues grow at 21 %

Mumbai, 30th October 2019: Indoco Remedies posted revenues of ₹ 285.6 crores during the second quarter of FY 2019-20, as against ₹ 235.9 crores, for the same quarter last year. For the quarter, the Company posted a profit of ₹ 7.3 crores, as against loss of ₹ 7.8 crores, same quarter last year.

Commenting on the second quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “During the second quarter, the Company’s India Business is at double digit growth at 17.2 % and also sequentially, India Business has grown by 15.3 %, which indicates good momentum. On the international business front, with the regulatory challenges easing out, the business in Europe will now take off, from here onwards”.

For the quarter ended **Sept’19**, the standalone financials are as under:

(₹ in Crores)

Particulars	July’19 - Sept’19	July’18 - Sept’18
Net Revenues	285.6	235.9
EBIDTA	32.1	11.8
Operating Profit	20.4	1.9
Profit After Tax	7.3	(7.8)
EPS (Face value ₹ 2/-) (Not annualized)	0.80	(0.85)

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, PMDA-Japan, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensiform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com